At Davos 2026, Novartis CEO Vas Narasimhan said regulatory clarity in the US and a rapid reshaping of the company’s supply ...

As Novartis turns the calendar on a new year, the Swiss drugmaker is elaborating further on plans for the $23 billion U.S.

Novartis CEO Vas Narasimhan told CNBC on Tuesday he expects the drugmaker's agreement with the U.S. government and its ...

While there were outliers, Marston said a major chunk of the investments are concentrated in a few key hubs: Pennsylvania and ...

Novartis has announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ...

The continent's pharma sector could be one of its worst hit by Trump's latest tariffs on some European countries.

Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro ...

Speaking to BioSpace at the J.P. Morgan Healthcare Conference, Novartis’ chief dealmaker Ronny Gal explains why the Swiss ...

Novartis signed on to become the National Football League’s first-ever corporate pharmaceutical partner. As part of the new multi-year deal, the Swiss pharma giant said it aims to empower football ...

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual ...